Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Milton Charles Weinstein, Ph.D.

Co-Author

This page shows the publications co-authored by Milton Weinstein and Paul Sax.
Connection Strength

0.830
  1. HIV cure strategies: how good must they be to improve on current antiretroviral therapy? PLoS One. 2014; 9(11):e113031.
    View in: PubMed
    Score: 0.149
  2. Should resistance testing be performed for treatment-naive HIV-infected patients? A cost-effectiveness analysis. Clin Infect Dis. 2005 Nov 01; 41(9):1316-23.
    View in: PubMed
    Score: 0.079
  3. Cost-effectiveness of enfuvirtide in treatment-experienced patients with advanced HIV disease. J Acquir Immune Defic Syndr. 2005 May 01; 39(1):69-77.
    View in: PubMed
    Score: 0.077
  4. Clinical Impact and Cost-effectiveness of Genotype Testing at Human Immunodeficiency Virus Diagnosis in the United States. Clin Infect Dis. 2020 03 17; 70(7):1353-1363.
    View in: PubMed
    Score: 0.054
  5. The Clinical and Economic Impact of Attaining National HIV/AIDS Strategy Treatment Targets in the United States. J Infect Dis. 2017 10 17; 216(7):798-807.
    View in: PubMed
    Score: 0.046
  6. Projecting 10-year, 20-year, and Lifetime Risks of Cardiovascular Disease in Persons Living With Human Immunodeficiency Virus in the United States. Clin Infect Dis. 2017 10 15; 65(8):1266-1271.
    View in: PubMed
    Score: 0.046
  7. Setting Performance Standards for a Cost-Effective Human Immunodeficiency Virus Cure Strategy in South Africa. Open Forum Infect Dis. 2017; 4(2):ofx081.
    View in: PubMed
    Score: 0.044
  8. Prioritizing HIV comparative effectiveness trials based on value of information: generic versus brand-name ART in the US. HIV Clin Trials. 2015 Nov; 16(6):207-18.
    View in: PubMed
    Score: 0.040
  9. The Cost-effectiveness and Budget Impact of 2-Drug Dolutegravir-Lamivudine Regimens for the Treatment of HIV Infection in the United States. Clin Infect Dis. 2016 Mar 15; 62(6):784-91.
    View in: PubMed
    Score: 0.040
  10. The clinical role and cost-effectiveness of long-acting antiretroviral therapy. Clin Infect Dis. 2015 Apr 01; 60(7):1102-10.
    View in: PubMed
    Score: 0.038
  11. Economic savings versus health losses: the cost-effectiveness of generic antiretroviral therapy in the United States. Ann Intern Med. 2013 Jan 15; 158(2):84-92.
    View in: PubMed
    Score: 0.033
  12. Assessing the performance of a computer-based policy model of HIV and AIDS. PLoS One. 2010 Sep 09; 5(9).
    View in: PubMed
    Score: 0.028
  13. The long-term benefits of genotypic resistance testing in patients with extensive prior antiretroviral therapy: a model-based approach. HIV Med. 2007 Oct; 8(7):439-50.
    View in: PubMed
    Score: 0.023
  14. Potential risks and benefits of HIV treatment simplification: a simulation model of a proposed clinical trial. Clin Infect Dis. 2007 Oct 15; 45(8):1062-70.
    View in: PubMed
    Score: 0.023
  15. The lifetime cost of current human immunodeficiency virus care in the United States. Med Care. 2006 Nov; 44(11):990-7.
    View in: PubMed
    Score: 0.021
  16. The survival benefits of AIDS treatment in the United States. J Infect Dis. 2006 Jul 01; 194(1):11-9.
    View in: PubMed
    Score: 0.021
  17. Routine human immunodeficiency virus testing: an economic evaluation of current guidelines. Am J Med. 2005 Mar; 118(3):292-300.
    View in: PubMed
    Score: 0.019
  18. Projecting the cost-effectiveness of adherence interventions in persons with human immunodeficiency virus infection. Am J Med. 2003 Dec 01; 115(8):632-41.
    View in: PubMed
    Score: 0.017
  19. Cost-effectiveness implications of the timing of antiretroviral therapy in HIV-infected adults. Arch Intern Med. 2002 Nov 25; 162(21):2478-86.
    View in: PubMed
    Score: 0.016
  20. Treatment for primary HIV infection: projecting outcomes of immediate, interrupted, or delayed therapy. J Acquir Immune Defic Syndr. 2002 Sep 01; 31(1):27-37.
    View in: PubMed
    Score: 0.016
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.